Welcome to our dedicated page for Iperionx SEC filings (Ticker: IPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IperionX Limited (IPX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. IperionX files annual reports on Form 20-F and furnishes current information on Form 6-K, including quarterly reports, sustainability reports, notices of annual general meeting, trading halt requests and press releases related to its titanium and critical minerals operations.
Through these filings, investors can review how IperionX describes its business as an American titanium metal and critical materials company that uses patented technologies to produce high performance titanium alloys from titanium minerals or scrap titanium. Annual and quarterly reports furnished as exhibits to Form 6-K outline the status of the Titanium Manufacturing Campus in Virginia, the Titan Critical Minerals Project in Tennessee, government funding arrangements, customer programs and risk factors associated with scaling titanium production and commercialization.
Filings also document U.S. Government support, including Defense Production Act Title III investments, Industrial Base Analysis and Sustainment awards, and the Small Business Innovation Research (SBIR) Phase III Indefinite Delivery, Indefinite Quantity contract that enables task orders for titanium components. These documents provide detail on how such programs are structured and how they relate to IperionX’s plans to expand titanium capacity and develop a mineral-to-metal supply chain.
On Stock Titan, users can view these SEC submissions as they are furnished to EDGAR and use AI-powered summaries to interpret complex sections. The platform highlights key elements of IperionX’s 20-F and 6-K exhibits, helping readers quickly understand disclosures about production capacity, government contracts, critical minerals resources, financial reporting practices and other material information contained in the company’s official filings.
IPERIONX Ltd President Toby Symonds purchased 3,000 American Depository Shares (ADS) in an open-market transaction at $30.63 per ADS on April 28, 2026, increasing his direct ADS holdings to 37,000 ADS.
Each ADS represents ten ordinary shares, which trade on the ASX, while the ADS trade on Nasdaq. As of this filing, he also directly owns 3,128,089 ordinary shares and holds sizeable option and performance-right positions over additional ordinary shares at exercise prices between A$4 and A$22.
IPERIONX Ltd Chief Financial Officer Marcela Rocha Castro reported new equity awards and updated holdings. On April 2, 2026, she received 52,258 Restricted Stock Units (RSUs) at A$0.00 per unit as part of her annual bonus. These RSUs are scheduled to vest in tranches, including 52,258 vesting in April 2029.
On the same date, she was also granted 127,993 options with an exercise price of A$11.00 per share, likewise described as part of her annual bonus. Each option gives the right to purchase one ordinary share.
After these awards, she directly holds 380,841 ordinary shares, 214,259 RSUs, and options over ordinary shares, including options linked to 216,672 underlying shares at an exercise price of A$5.00 expiring in 2029 and the new 127,993 options at A$11.00 exercisable from 2029 and expiring in 2030. Ordinary shares are traded on the Australian Stock Exchange.
IPERIONX Ltd director Lorraine M. Martin bought 4,755 American Depository Shares (ADS) in an open-market purchase. The ADS were acquired at an average price of $31.4647 per ADS, and each ADS is equivalent to ten Ordinary Shares, or 47,550 Ordinary Shares in total.
After this transaction, Martin directly holds 4,755 ADS, 1,177,138 Ordinary Shares traded on the ASX, and 90,216 Restricted Stock Units (RSUs). According to the filing, 76,054 RSUs vest in December 2026 and 14,162 RSUs vest in December 2027, reflecting a sizable ongoing equity stake tied to future performance and service.
IPERIONX Ltd Chief Executive Officer Anastasios Arima reported an open-market purchase of 110,000 Ordinary Shares on April 28, 2026 at an average price of $4.4875 per share. Following this transaction, he directly holds 12,316,782 Ordinary Shares.
He also reports various equity incentives, including options over 639,205 Ordinary Shares at A$22 and 564,759 Ordinary Shares at A$18, plus multiple performance rights series and 128,000 American Depository Shares, each ADS being exchangeable into ten Ordinary Shares.
IPERIONX Ltd Executive Chairman Todd Hannigan reported significant open-market share purchases. On April 28, 2026, he bought 220,000 Ordinary Shares at an average price of $4.4819 per share, followed by another purchase of 260,000 Ordinary Shares at $4.1991 per share on April 29, 2026.
After these trades, he directly holds 26,108,334 Ordinary Shares, along with 454,464 Restricted Stock Units, 500,000 American Depository Shares, and several option and performance rights awards over additional Ordinary Shares. One ADS is exchangeable for 10 Ordinary Shares, highlighting a substantial overall equity exposure.
IperionX Limited reports a major step-up in operations, moving its Virginia titanium campus from commissioning to 24/7 continuous production using its HAMR™ and HSPT™ technologies. March HAMR™ powder output reached about 4.2 metric tons, an annualized rate of roughly 50 tpa, with a target of ~200 tpa by end of CY2026.
The company is expanding downstream press-and-sinter and additive manufacturing capacity to convert powders into higher-value titanium components for defense, automotive and consumer electronics customers. U.S. Department of War support now totals up to US$59.8 million in obligated grants plus an SBIR pathway of up to US$99 million, alongside 290 metric tons of scrap feedstock transferred at no cost.
As of March 31, 2026, IperionX held US$48.2 million cash, after a quarterly operating cash outflow of US$16.3 million, and estimates a June 30, 2026 cash balance of US$36–40 million. The Titan Critical Minerals Project DFS is nearing completion for mid‑2026, positioning Titan as a potential U.S. source of titanium, zircon and heavy rare earths.
IperionX Limited reports a major step-up in operations, moving its Virginia titanium campus from commissioning to 24/7 continuous production using its HAMR™ and HSPT™ technologies. March HAMR™ powder output reached about 4.2 metric tons, an annualized rate of roughly 50 tpa, with a target of ~200 tpa by end of CY2026.
The company is expanding downstream press-and-sinter and additive manufacturing capacity to convert powders into higher-value titanium components for defense, automotive and consumer electronics customers. U.S. Department of War support now totals up to US$59.8 million in obligated grants plus an SBIR pathway of up to US$99 million, alongside 290 metric tons of scrap feedstock transferred at no cost.
As of March 31, 2026, IperionX held US$48.2 million cash, after a quarterly operating cash outflow of US$16.3 million, and estimates a June 30, 2026 cash balance of US$36–40 million. The Titan Critical Minerals Project DFS is nearing completion for mid‑2026, positioning Titan as a potential U.S. source of titanium, zircon and heavy rare earths.
IPERIONX Ltd Chief Financial Officer Marcela Rocha Castro received new equity awards. She was granted options over 127,993 IPX Ordinary Shares at an exercise price of A$11 per share and 52,258 restricted stock units, both dated April 2, 2026.
Each option allows the purchase of one ordinary share at the stated conversion price. Following these awards, she directly holds 340,795 ordinary shares and 214,259 restricted stock units. Existing options with a conversion price of A$5 over IPX Ordinary Shares remain outstanding, and the restricted stock units vest on a schedule extending to April 2029.
IPERIONX Ltd President Toby Edgcumbe Symonds reported new equity awards and updated holdings. He received 226,047 performance rights tied to an A$18 share price hurdle and service conditions, plus 536,521 options at A$18 and 607,244 options at A$22, each over IPX ordinary shares. These are compensation-related grants, not market purchases or sales. After these awards, he reports direct ownership of 3,188,146 ordinary shares, 110,000 American Depositary Shares, and substantial additional performance rights and restricted stock units that may convert into ordinary shares if their conditions are met.
Arima Anastasios reported acquisition or exercise transactions in this Form 4 filing.
IPERIONX Ltd Chief Executive Officer Anastasios Arima received multiple new equity awards. On 2026-04-02, he was granted 237,944 performance rights tied to an A$18.00 stock-price hurdle and four years of continuous service, each convertible into one ordinary share once the performance criteria are met.
He was also granted options over 564,759 IPX ordinary shares at A$18.00 and 639,205 shares at A$22.00, each exercisable from 2030-04-02 and expiring on 2031-04-02. These are compensation-related awards, not open-market share purchases or sales.
Following these grants, Arima holds 12,206,782 ordinary shares directly, 128,000 American Depository Shares listed on Nasdaq (each equal to ten ordinary shares), 435,806 performance rights at each of A$6.00, A$7.00 and A$8.00, and 738,576 restricted stock units.